• Notice

Kansai Forum] Creating a New Era of Medical Care - Venture Support Mechanisms - June 21, 2020 (Sun.) 11:00 a.m. @ Kobe

【関西フォーラム】新時代の医療を創る〜ベンチャー支援の仕組みを考える〜 2020年6月21日(日)11:00@神戸
panel discussion
Creating a New Era of Medical Care - Venture Support Mechanisms -.

Riverness will sponsor the event.Hyper Interdisciplinary Conference in Kansai Forum 2020(Sunday, June 21, 2020), in the panel discussion "Creating a New Era of Healthcare - Considering the Mechanism of Venture Support".
The event will be held at the following location.

The Japan Society for Hyperdifferentiation Kansai Forum 2020 WEB:https://hic.lne.st/conference/osaka2020/

In the past, when looking at medical applications of research, there were many hurdles to overcome, such as clinical trials and regulatory approval, and the time required for social implementation was considered to be long, taking more than a decade. However, as a result of the crisis of globally spreading infectious diseases (COVID-19) and the united efforts of mankind, social implementation of research is progressing innovatively. We can learn from the current state of transition in medicine and glimpse a new era in which research can be promptly applied to medical care. In this session, we will discuss the new era of medicine from the angle of a new mechanism of venture support.

We have prepared a program of discussions among researchers, venture companies, and large corporations from various perspectives, not limited to the themes of this session. We are currently accepting applications for audience participation. Please visit the conference website (see below).


Creating a New Era of Medical Care - Venture Support Mechanisms -.

Date: Sunday, June 21, 2020, 11:00-12:00
Venue: Kobe International Conference Center (6-9-1 Minatojima-nakamachi, Chuo-ku, Kobe 650-0046, Japan)
Closest Station: Shimin Hiroba Station (Portliner)


Bayer Yakuhin K.K.
Director, Open Innovation Center
Shunichi Takahashi

D. in Chemistry from the Graduate School of Science and Engineering, Aoyama Gakuin University. After joining Mitsui Pharmaceutical Industries (at that time), he was transferred to the Cardiovascular Research Division of the U.S. subsidiary Barlex Biosciences at Nihon Searing after the business integration, where he worked in the Cardiovascular Research Department and Immunology Research Department. After the business integration with Bayer Yakuhin, he worked as a senior researcher in the Regenerative Medicine Research Division at Kobe Research Center, Manager of the Cardiovascular Area of Project Management in the Development Division, and Director of the Medical Affairs Primary Care Department before becoming the Director of the Open Innovation Center in June 2014.


Representative Director and CEO, AMI, Inc.
Shinpei Ogawa

Born in Kumamoto City, Kumamoto Prefecture. Graduated from Kumamoto University Faculty of Medicine. Cardiologist.Established AMI Corporation in November 2015. Currently developing a "super stethoscope," a stethoscope that assists in the diagnosis of cardiac disease, and a tele-aural video chat system that realizes high-quality telemedicine; working toward the practical application of the telemedicine service "Cloud Kenshin" in Minamata City, Kumamoto Prefecture from 2018. Major awards include the 1st MedTech Grand Prix KOBE Grand Prize, C-startup Pitch Grand Prize, etc. In 2019, he was selected as Real Tech Venture of the Year in the Growth category.


Representative Director, Cuor Co.
Mr. Ryusho Kariya

Born in Kochi Prefecture. After qualifying as a pharmacist at Kobe Gakuin University Faculty of Pharmaceutical Sciences, he entered the Graduate School of Medical Education, Kumamoto University, where he engaged in research on AIDS-related malignant lymphoma and the development of novel hyper-immunodeficient mice. After obtaining his PhD (Medicine), he became a postdoctoral researcher and engaged in the development of novel anti-cancer drugs using the established super-immunodeficient mice. Currently, he serves as the president of Cuor Inc. which he established in 2018 and as a specially-appointed assistant professor at Kumamoto University's Joint Research Center for Human Retroviridae.




Vice President CTO and Representative Director, Liverness, Inc.
Jyo Inoue

D. in Pharmaceutical Sciences from Tokyo University of Pharmacy and Life Sciences. He is a founding member of LIVERNESS. After completing his doctoral studies, he worked as an assistant professor and lecturer at the Faculty of Science, Kitasato University, and an assistant professor at the Graduate School of Medicine, Kyoto University, before being appointed and concurrently serving as a specially-appointed associate professor at the Institute for Advanced Biosciences, Keio University in 2015, and as a professor of advanced pharmacy at the Faculty of Pharmaceutical Sciences, Kumamoto University and a visiting professor at Keio University's Faculty of Pharmaceutical Sciences in 2018. While conducting research and development, he is a researcher involved in launching joint research projects with universities and research institutions and supporting the establishment of research institutes.


The Japan Society for Hyper-Differential Research Kansai Forum 2020 Overview

Conference theme: The Circle of Knowledge for a Sustainable Society - Medicine and Environment in the After Corona
Date and time of the event:
June 21 (Sun.) 9:00-17:30
Organized by: Liverness Co.
Venue: Kobe International Conference Center
Participation fee: Free for academics and presenters, 50,000 yen for companies
    *Free of charge for partners and those willing to serve as judges
Convention URL:https://hic.lne.st/conference/osaka2020/

<Contact us for more information.
LIVANES Corporation, Osaka Head Office (Attn: Nakaemasa, Isogai)
TEL:050-1743-9799 E-mail:[email protected]